Tag Archives: Survival

How Long am I Going to Live With my Metastatic Breast Cancer?

Posted on February 6, 2011 by wngai

Metastatic breast cancer (MBC) is a disease that is essentially incurable.  Women with MBC are given chemotherapy at some stage of their illness to extend their lives.  When starting chemotherapy for MBC, most women would like to know how the … Continue reading →

Posted in Breast cancer, Cancer | Tagged , , , , , | Comments Off on How Long am I Going to Live With my Metastatic Breast Cancer?

Yunzhi Slows Progression of Advanced Non-small Cell Lung Cancer

Posted on February 6, 2011 by wngai

Non-small cell lung cancer (NSCLC) is a leading cause of cancer deaths, but most patients (over 69%) were diagnosed at advanced stages.  Although polysaccharide peptides (PSP), isolated from the fungus Yunzhi (Coriolus versicolor), have been reported to have anti-tumor effects … Continue reading →

Posted in Alternative Medicine, Cancer, Non Small Cell Lung Cancer | Tagged , , , , , , , , , , | Comments Off on Yunzhi Slows Progression of Advanced Non-small Cell Lung Cancer

Bevacizumab Beneficial in Newly Diagnosed Glioblastoma?

Posted on December 22, 2010 by wngai

A large study of patients with newly diagnosed glioblastoma multiforme suggests that the addition of bevacizumab (Avastin) and irinotecan (Camptosar) to standard chemoradiation can extend survival (progression and overall survival) by 6 months.  Bevacizumab (Avastin) is an inhibitor of vascular … Continue reading →

Posted in Cancer, Glioblastma | Tagged , , , , , , , , , | Comments Off on Bevacizumab Beneficial in Newly Diagnosed Glioblastoma?

FDA Approves Halaven for Late-Stage Breast Cancer

Posted on November 22, 2010 by wngai

Good news for patients with late stage metastatic breast cancer.  The US Food and Drug Administration (FDA) approved eribulin mesylate injection (Halaven; Eisai, Inc) for the treatment of metastatic breast cancer in patients who have received at least 2 prior … Continue reading →

Posted in Breast cancer, Cancer | Tagged , , , , , , , , , , , , , , , | Comments Off on FDA Approves Halaven for Late-Stage Breast Cancer

It is Better for Cancer Patients to Die at Home

Posted on November 14, 2010 by wngai

Cancer patients who die at home do so more peacefully and their caregivers also end up doing better emotionally, reported in the September 13th issue in the Journal of Clinical Oncology  Wright’s team studied 342 terminal cancer patients and their … Continue reading →

Posted in Acute Promyelocytic Leukemia, Breast cancer, Cancer, Colorectal cancer, Esophageal Cancer, Gallbladder cancer, Gastric Cancer, Head and Neck Cancer, Liver Cancer, Lung Cancer, Lymphoma, Melanoma, Nasopharyngeal Cancer, Non Small Cell Lung Cancer, Non-Hodgkin's Disease, Ovarian Cancer, Pancreatic Cancer, Prostate cancer, Small Cell Lung Cancer | Tagged , , , , , | Comments Off on It is Better for Cancer Patients to Die at Home

First-Line Erlotinib Triples Progression-Free Survival in NSCLC in Chinese Population

Posted on October 16, 2010 by wngai

First-line erlotinib (Tarceva) tripled the progression-free survival in advanced non–small cell lung carcinoma (NSCLC) patients who had endothelial growth factor receptor (EGFR)-activating mutation, according to the OPTIMAL study presented at the 35th European Society for Medical Oncology Congress. The study … Continue reading →

Posted in Cancer, Lung Cancer, Non Small Cell Lung Cancer | Tagged , , , , , , , , , , | Comments Off on First-Line Erlotinib Triples Progression-Free Survival in NSCLC in Chinese Population

Cetuximab (Erbitux) Reduces Disease Progression in Triple Negative Breast Cancer

Posted on October 16, 2010 by wngai

Patients with triple negative breast cancer usually have poor prognosis, but a new drug might soon be available to improve the survival in these patients.   Mid-stage study results presented at the European Society for Medical Oncology congress indicated that cetuximab(Erbitux) … Continue reading →

Posted in Breast cancer, Cancer | Tagged , , , , , | Comments Off on Cetuximab (Erbitux) Reduces Disease Progression in Triple Negative Breast Cancer

Novel Agent Significantly Improves Survival in Men with Advanced Prostate Cancer

Posted on October 16, 2010 by wngai

Great news for patients with advanced prostate cancer.  A new investigational agent, abiraterone acetate, was shown to significantly improved survival in men with metastatic castration-resistant prostate cancer.  Abiraterone acetate is an investigational agent being developed by Ortho Biotech.  It acts … Continue reading →

Posted in Cancer, Prostate cancer | Tagged , , , , , , , , | Comments Off on Novel Agent Significantly Improves Survival in Men with Advanced Prostate Cancer

HER2-positive Breast Cancer with Brain Metastases? Use Lapitinibi (Tykerb) and Capecitibine (Xeloda) but NOT Trastuzumab (Herceptin)

Posted on September 27, 2010 by wngai

Human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) is a disease that accounts for up to one third of all invasive breast tumors. The natural history of this disease, however, has been dramatically improved with the introduction of … Continue reading →

Posted in Breast cancer, Cancer | Tagged , , , , , , , , , , | Comments Off on HER2-positive Breast Cancer with Brain Metastases? Use Lapitinibi (Tykerb) and Capecitibine (Xeloda) but NOT Trastuzumab (Herceptin)

A New Treatment Option for patients with Gastric Cancer

Posted on September 12, 2010 by wngai

 Gastric cancer is the fourth most commonly diagnosed cancer and the second most common cause of cancer-related deaths worldwide.  Previous study has found that patients with operable disease have a 5-year survival rate of 36%.  In patients with advanced or … Continue reading →

Posted in Cancer, Gastric Cancer | Tagged , , , , , , , , , | Comments Off on A New Treatment Option for patients with Gastric Cancer